Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessDevelopment of a mammalian cell culture process for rapid Clinical-Scale production of novel Influenza Nanoparticle vaccines
-
Article
Open AccessCHO-DHFR cell line development platform: Application of Clonepix and Automated Mini Bioreactor (AMBR) technologies to meet accelerated timelines
-
Article
Open AccessAn avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
A novel avian influenza subtype, A/H7N9, emerged in 2013 and represents a public health threat with pandemic potential. We have previously shown that DNA vaccine priming increases the magnitude and quality of ...